Guidelines & Consensus
Updated CAP-ASCP Guideline on HER2 Testing in Advanced Gastroesophageal Adenocarcinoma
Bartley et alArchives of pathology & laboratory medicine

The College of American Pathologists (CAP), in collaboration with the American Society for Clinical Pathology (ASCP), has released an updated evidence-based clinical practice guideline for human epidermal growth factor receptor 2 (HER2, ERBB2) testing in advanced gastroesophageal adenocarcinoma (GEA). Convened following National Academy of Medicine standards, the expert panel conducted a systematic literature review of evidence published since the 2016 CAP/ASCP/ASCO guideline and applied the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology.
The panel developed three strong recommendations. In addition, among six statements from the 2016 guideline released for public comment, four were reaffirmed as good practice statements for HER2 assessment in advanced GEA, while two statements were archived.
Regarding clinical implementation, the guideline recommends that testing at the initial diagnosis of advanced GEA be conducted on the highest-quality tumor specimen available. Immunohistochemistry followed by in situ hybridization, if indicated, should serve as the primary modality for HER2 assessment, while genomic testing may be utilized concurrently or subsequently to guide clinical decision-making. For patients being considered for subsequent lines of therapy after disease progression, testing may be performed on relapsed or recurrent disease, with tissue identified as the preferable specimen type while liquid biopsy remains an acceptable alternative.
Key Takeaways
- The updated guideline recommends primary HER2 assessment via immunohistochemistry followed by in situ hybridization if indicated on the highest-quality tumor specimen at initial diagnosis of advanced gastroesophageal adenocarcinoma, with concurrent or subsequent genomic testing permitted.
- For patients evaluated for subsequent therapy following disease progression, HER2 testing may be performed on relapsed or recurrent tumor specimens, with tissue preferred though liquid biopsy is acceptable.
Read the original sourceArchives of pathology & laboratory medicine
